Hypertrophic cardiomyopathy in patients with diabetes mellitus associated with mitochondrial tRNA(Leu)(UUR) gene mutation. 1995

R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
Division of Endocrinology and Metabolism, Hyogo Medical Center for Adults.

Left ventricular function and morphology were assessed using M-mode echocardiography in 3 patients with diabetes mellitus associated with mitochondrial tRNA(Leu)(UUR) gene mutation, who were free of clinical, electrocardiographic, or thallium scan evidence of ischemic heart disease. Echocardiograms revealed hypertrophic cardiomyopathy in all 3 patients. Hypertrophy of the interventricular septum was mild in Cases 1 and 3 (12 and 13 mm, respectively) and severe in Case 2 (22 mm) (normal 7-10 mm). When they had neither signs nor symptoms suggestive of congestive heart failure, percentage fractional shortening (%FS), an index of wall motion of the left ventricle (normal > 28%), was normal in Cases 2 and 3 (28 and 32%, respectively) whereas it was slightly decreased in Case 1 (22%). In Case 1 with mild hypertrophy, the development of congestive heart failure was associated with a marked decrease in %FS to 13%; this patient responded well to diuretics and captopril and %FS rose to 22%. However, a mild decrease in %FS to 21% caused congestive heart failure in Case 2 with severe hypertrophy. His response to treatment was marginal. The present study indicates that mitochondrial DNA analysis should be done in patients with diabetic cardiomyopathy, and that sequential echocardiography is invaluable for the detection of hypertrophic cardiomyopathy and the management of subsequent myocardial dysfunction in patients with mitochondrial diabetes mellitus and cardiomyopathy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D004272 DNA, Mitochondrial Double-stranded DNA of MITOCHONDRIA. In eukaryotes, the mitochondrial GENOME is circular and codes for ribosomal RNAs, transfer RNAs, and about 10 proteins. Mitochondrial DNA,mtDNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012346 RNA, Transfer, Amino Acyl Intermediates in protein biosynthesis. The compounds are formed from amino acids, ATP and transfer RNA, a reaction catalyzed by aminoacyl tRNA synthetase. They are key compounds in the genetic translation process. Amino Acyl tRNA,Transfer RNA, Amino Acyl,tRNA-Amino Acyl,Amino Acyl T RNA,Acyl tRNA, Amino,Acyl, tRNA-Amino,tRNA Amino Acyl,tRNA, Amino Acyl
D014463 Ultrasonography The visualization of deep structures of the body by recording the reflections or echoes of ultrasonic pulses directed into the tissues. Use of ultrasound for imaging or diagnostic purposes employs frequencies ranging from 1.6 to 10 megahertz. Echography,Echotomography,Echotomography, Computer,Sonography, Medical,Tomography, Ultrasonic,Ultrasonic Diagnosis,Ultrasonic Imaging,Ultrasonographic Imaging,Computer Echotomography,Diagnosis, Ultrasonic,Diagnostic Ultrasound,Ultrasonic Tomography,Ultrasound Imaging,Diagnoses, Ultrasonic,Diagnostic Ultrasounds,Imaging, Ultrasonic,Imaging, Ultrasonographic,Imaging, Ultrasound,Imagings, Ultrasonographic,Imagings, Ultrasound,Medical Sonography,Ultrasonic Diagnoses,Ultrasonographic Imagings,Ultrasound, Diagnostic,Ultrasounds, Diagnostic

Related Publications

R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
April 1998, Japanese circulation journal,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
May 1997, Chinese medical journal,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
January 1996, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
February 1995, Diabetologia,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
April 1995, Zhonghua yi xue za zhi,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
May 1993, Lancet (London, England),
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
July 1997, Diabetes care,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
January 1997, Journal of the neurological sciences,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
September 1997, Metabolism: clinical and experimental,
R Yoshida, and Y Ishida, and K Abo, and T Hozumi, and H Ueno, and H Shiotani, and M Kishimoto-Hashiramoto, and M Hashiramoto, and K Matsunaga, and M Kasuga
January 1998, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!